NCT01836939View on ClinicalTrials.gov

Safety and Effectiveness of CNDO 201Trichuris Suis Ova (TSO) for the Treatment of Moderate to Severe Plaque Psoriasis

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions
Psoriasis
Interventions
DRUG

TSO 2500

TSO 2500: 2500 embryonated, viable TSO/15 mL/day every 2 weeks X 10 weeks

DRUG

TSO 7500

12 weeks of treatment with TSO 2500 ova or TSO 7500 ova given every 2 weeks (a total of 6 doses).

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

Sponsors
All Listed Sponsors
collaborator

Coronado Biosciences, Inc.

INDUSTRY

lead

Mark Lebwohl

OTHER